España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Intra-Cellular Therapies
ITCI
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$83.45
-0.69
-0.82%
At close: -
$84.32
0.87
1.04%
After Hours: Dec 20, 4:09 PM EDT
Get Report
Comment
Intra-Cellular Therapies (ITCI) Forecast
News
Earnings
Intra-Cellular Therapies (ITCI) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Intra-Cellular Therapies (NASDAQ:ITCI) Stock
Intra-Cellular Therapies Stock (NASDAQ: ITCI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 11, 2024
Intra-Cellular Therapies Presents Data From T...
Benzinga Newsdesk
Tuesday, December 03, 2024
Intra-Cellular Therapies Submitted A Suppleme...
Benzinga Newsdesk
Tuesday, November 05, 2024
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Vandana Singh
Intra-Cellular Therapies Reports Results From...
Benzinga Newsdesk
Monday, November 04, 2024
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Benzinga Insights
JP Morgan Maintains Overweight on Intra-Cellu...
Benzinga Newsdesk
Thursday, October 31, 2024
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Wednesday, October 30, 2024
Intra-Cellular Therapies shares are trading h...
Benzinga Newsdesk
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
CAPLYTA Raised 2024 Net Product Sales Guidanc...
Benzinga Newsdesk
Intra-Cellular Therapies Q3 2024 GAAP EPS $(0...
Benzinga Newsdesk
Tuesday, October 29, 2024
Earnings Preview For Intra-Cellular Therapies
Benzinga Insights
Friday, October 11, 2024
Morgan Stanley Maintains Overweight on Intra-...
Benzinga Newsdesk
Friday, October 04, 2024
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Benzinga Insights
RBC Capital Maintains Outperform on Intra-Cel...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Friday, September 06, 2024
Expert Ratings For Intra-Cellular Therapies
Benzinga Insights
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Avi Kapoor
Piper Sandler Upgrades Intra-Cellular Therapi...
Benzinga Newsdesk
Wednesday, August 21, 2024
JP Morgan Maintains Overweight on Intra-Cellu...
Benzinga Newsdesk
Thursday, August 08, 2024
RBC Capital Maintains Outperform on Intra-Cel...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Int...
Benzinga Newsdesk
UBS Maintains Neutral on Intra-Cellular Thera...
Benzinga Newsdesk
Goldman Sachs Maintains Neutral on Intra-Cell...
Benzinga Newsdesk
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Wednesday, August 07, 2024
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
Benzinga Insights
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Intra-Cellular Therapies Announced That Sanje...
Benzinga Newsdesk
Intra-Cellular Therapies Sees 2024 CAPLYTA Ne...
Benzinga Newsdesk
Intra-Cellular Therapies Q2 2024 GAAP EPS $(0...
Benzinga Newsdesk
Monday, July 22, 2024
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Benzinga Insights
Needham Maintains Buy on Intra-Cellular Thera...
Benzinga Newsdesk
Tuesday, June 25, 2024
UBS Downgrades Intra-Cellular Therapies to Ne...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Intra-Ce...
Benzinga Newsdesk
Sunday, June 23, 2024
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Lekha Gupta
Friday, June 21, 2024
Mizuho Maintains Buy on Intra-Cellular Therap...
Benzinga Newsdesk
Thursday, June 20, 2024
Canaccord Genuity Maintains Buy on Intra-Cell...
Benzinga Newsdesk
Tuesday, June 18, 2024
Needham Maintains Buy on Intra-Cellular Thera...
Benzinga Newsdesk
Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Vandana Singh
Market-Moving News for June 18th
Benzinga Newsdesk
Intra-Cellular Therapies shares are trading h...
Benzinga Newsdesk
Intra-Cellular Therapies Announces Topline Re...
Benzinga Newsdesk
Friday, June 14, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Wednesday, June 12, 2024
Where Intra-Cellular Therapies Stands With Analysts
Benzinga Insights
JP Morgan Maintains Overweight on Intra-Cellu...
Benzinga Newsdesk
Wednesday, May 08, 2024
Analyst Ratings For Intra-Cellular Therapies
Benzinga Insights
Needham Reiterates Buy on Intra-Cellular Ther...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch